

26 January 2024

Scancell Holdings plc
("Scancell" or the "Company")

Notice of Interim Results and Presentation

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, will announce its interim results for the six months ended 31 October 2023 on Tuesday 30 January 2024.

Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalanathan, Chief Financial Officer, will host a live webcast and Q&A session for analysts and investors at 14:00 GMT. If you would like to join the webcast, please follow this link: <https://www.lsegissuerservices.com/spark/ScancellHoldings/events/f581274b-146c-4a89-af15-05bcae874775>

A replay of the webcast will be made available shortly afterwards.

Please contact ICR Consilium for further details.

A copy of the presentation will also be made available on the Company's [news section](#) following the presentation.

-ENDS-

For further information, please contact:

Scancell Holdings plc +44 (0) 20 3709 5700

Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)

Nick Adams/Nick Harland (Corporate Broking)

WG Partners LLP (Joint Broker) +44 (0) 20 3705 9330

David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

ICR Consilium +44 (0) 20 3709 5700

Mary-Jane Elliott/Matthew Neal/Chris Welsh
scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant

unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>